⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL628534 | 0.97 | P2RX7 (0.41) | — | |
| Pyridine SCHEMBL8144132 | 0.88 | NAPRT (0.41) | — | |
| Acetic Acid SCHEMBL3228897 | 0.86 | P2RX7 (0.43) | — | |
| SCHEMBL1938612 | 0.77 | SMN1; SMN2 (0.55) | — | |
| SCHEMBL795730 | 0.74 | — | — | |
| SCHEMBL15588816 | 0.72 | P2RX7 (0.40) | — | |
| SCHEMBL7992613 | 0.72 | — | — | |
| SCHEMBL28079692 | 0.72 | LMNA (0.39) | — | |
| SCHEMBL2924227 | 0.71 | LMNA (0.33) | — | |
| SCHEMBL2461881 | 0.71 | F10 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319686-B2 | Process for the preparation of tetrahydropyridopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20220098189-A1 | PROCESS FOR THE PREPARATION OF TETRAHYDROPYRIDOPYRIMIDINES | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | claimed |
| EP-3911649-A1 | A PROCESS FOR THE PREPARATION OF TETRAHYDROPYRIDOPYRIMIDINES | F. Hoffmann-La Roche AG (CH) | 2021-11-24 | — | — | EP | claimed |
| CN-113302192-A | Process for preparing tetrahydropyridopyrimidines | 豪夫迈·罗氏有限公司 | 2021-08-24 | — | — | CN | claimed |
| WO-2020148352-A1 | A PROCESS FOR THE PREPARATION OF TETRAHYDROPYRIDOPYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-07-23 | — | — | WO | claimed |
| US-20110263623-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-2331513-A1 | PROCESS FOR PREPARATION OF BOSENTAN | Cadila Healthcare Limited (IN) | 2011-06-15 | — | — | EP | claimed |
| WO-2010032261-A1 | PROCESS FOR PREPARATION OF BOSENTAN | CADILA HEALTHCARE LIMITED (IN) | 2010-03-25 | — | — | WO | claimed |
| EP-0841326-B1 | Process for the preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2001-05-16 | — | — | EP | claimed |
| CN-1182082-A | Preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-05-20 | — | — | CN | claimed |
| US-12319686-B2 | Process for the preparation of tetrahydropyridopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-12037326-B2 | Diaryl-azole compound and formulation for controlling harmful organism | NIPPON SODA CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11746100-B2 | Cycloalkyl pyrimidines as ferroportin inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| CN-1182082-A | Preparation of pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 1998-05-20 | — | — | CN | disclosed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5541186-A | ENDOTHELIN RECEPTOR INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1996-07-30 | — | — | US | disclosed |
| US-5420129-A | Treatment of hypertension, ischemia, vasospasms, angina | HOFFMANN-LA ROCHE INC. (US) | 1995-05-30 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |